The present invention describes compounds that are safe, nontoxic, noncorrosive, and nonirritating and methods thereof that are antibacterial and antiviral (encompassing cancer as well or chemotherapy) for the prevention and treatment of individuals suffering from infectious diseases. The compounds of the instant invention can also be administered to those individuals who are in need of such therapy such as those who have thymus diseases or those who are old enough that the thymus gland does not function anymore (thymus involution). This method can also be employed in healthy subjects as a preventive measure against such infections. The method relies on administering to infected patient healthy whole blood or healthy plasma transfusion procured from healthy children where it is permissible by law (emphasis added) or from healthy adults ages 18 to 20 years. This as a result will endogenously regenerate the thymus gland via the process of thymopoiesis to produce mature T cells, which are the most important cells in adaptive immunity for combating bacterial and viral infections. The compounds of the instant invention can be those, but not limited to, hormones secreted by the thymus gland and their synthetic counterparts, a combination of them, their active compounds, their progenitors, and their stimulating and mediated compounds and their mixtures thereof all can be used in the instant invention.

Disclosed herein are contractile cell constructs, methods for using them to treat disease, and methods for making them.

Disclosed herein are contractile cell constructs, methods for using them to treat disease, and methods for making them.

Provided herein is a method of treating medulloblastoma or glioblastoma in a subject by administering to the subject a PI3K activator (e.g., thymosin β-4 or a derivative thereof) and one or more chemotherapeutic agents and/or radiation. The combination therapy is effective in the treatment of medulloblastoma or glioblastoma characterized by cells with elevated p53 levels.

Provided herein is a method of treating medulloblastoma or glioblastoma in a subject by administering to the subject a PI3K activator (e.g., thymosin β-4 or a derivative thereof) and one or more chemotherapeutic agents and/or radiation. The combination therapy is effective in the treatment of medulloblastoma or glioblastoma characterized by cells with elevated p53 levels.

Disclosed herein are contractile cell constructs, methods for using them to treat disease, and methods for making them.

Disclosed herein are contractile cell constructs, methods for using them to treat disease, and methods for making them.

The present invention provides methods for preventing, treating, or reducing the severity of sepsis, severe sepsis or septic shock, including bacterial, viral, and fungal infections, and including infections of more complex etiology. The invention involves the administration of an alpha thymosin peptide regimen. In certain embodiments, the alpha thymosin peptide regimen is scheduled or timed with respect to potential, expected and/or diagnosed sepsis, severe sepsis or septic shock. In certain embodiments, the patient is immunodeficient or immunocompromised, and/or the patient is hospitalized or scheduled for hospitalization, such that the regimen of alpha thymosin peptide peptide helps to protect the patient from, or reduce the severity of, sepsis, severe sepsis or septic shock.

Methods of treating dry eye syndrome (DES) with an effective amount of thymosin beta 4 (T4), T4 fragments, T4 isoforms, T4 derivatives, peptide agents including amino acid sequence LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO:2], or variants thereof are provided. The presently disclosed subject matter provides methods of increasing tear volume, increasing tear film stability, decreasing ocular surface damage, and decreasing ocular discomfort by delivering compositions of thymosin beta 4 or fragments thereof to subjects in need.

A method for treatment and/or reduction of occurrence of immune checkpoint inhibitor related immune adverse effects in a subject in need thereof, includes administering thymosin alpha 1 to the subject. The immune checkpoint inhibitor related immune adverse effects can include colitis, diarrhea, rash, elevated alanine amino transferase (ALT), hypothyroidism, or hypophysitis.